SG11202101397TA - Biomarkers for cancer therapy - Google Patents

Biomarkers for cancer therapy

Info

Publication number
SG11202101397TA
SG11202101397TA SG11202101397TA SG11202101397TA SG11202101397TA SG 11202101397T A SG11202101397T A SG 11202101397TA SG 11202101397T A SG11202101397T A SG 11202101397TA SG 11202101397T A SG11202101397T A SG 11202101397TA SG 11202101397T A SG11202101397T A SG 11202101397TA
Authority
SG
Singapore
Prior art keywords
biomarkers
cancer therapy
cancer
therapy
Prior art date
Application number
SG11202101397TA
Inventor
Xiang Li
Yiyou Chen
Original Assignee
Beijing Percans Oncology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/100206 external-priority patent/WO2020034061A1/en
Priority claimed from PCT/CN2018/115826 external-priority patent/WO2020097901A1/en
Application filed by Beijing Percans Oncology Co Ltd filed Critical Beijing Percans Oncology Co Ltd
Publication of SG11202101397TA publication Critical patent/SG11202101397TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16Assays for determining copy number or wherein the copy number is of special importance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
SG11202101397TA 2018-08-13 2019-08-12 Biomarkers for cancer therapy SG11202101397TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2018/100206 WO2020034061A1 (en) 2018-08-13 2018-08-13 Biomarkers for cancer therapy
PCT/CN2018/115826 WO2020097901A1 (en) 2018-11-16 2018-11-16 Biomarkers for cancer therapy
PCT/US2019/046124 WO2020036852A1 (en) 2018-08-13 2019-08-12 Biomarkers for cancer therapy

Publications (1)

Publication Number Publication Date
SG11202101397TA true SG11202101397TA (en) 2021-03-30

Family

ID=69525762

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101397TA SG11202101397TA (en) 2018-08-13 2019-08-12 Biomarkers for cancer therapy

Country Status (11)

Country Link
US (1) US20210180141A1 (en)
EP (1) EP3836909A4 (en)
JP (2) JP2021533774A (en)
KR (1) KR20210044251A (en)
CN (1) CN113226318A (en)
AU (1) AU2019321289A1 (en)
BR (1) BR112021002622A2 (en)
CA (1) CA3109605A1 (en)
MX (1) MX2021001749A (en)
SG (1) SG11202101397TA (en)
WO (1) WO2020036852A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
WO2021155580A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating cancer
WO2021155581A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating b-cell lymphomas
WO2022061595A1 (en) * 2020-09-23 2022-03-31 Xiang Li Notch1 biomarkers for cancer therapy
CN114184693B (en) * 2021-10-14 2023-10-13 重庆医科大学 Application of 4-hydroxyphenylacetic acid as marker in preparation of diagnosis kit for sepsis encephalopathy
CN116370476B (en) * 2023-04-21 2024-01-30 遵义医科大学 Chemotherapy medicine composition and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111213A1 (en) * 2004-05-18 2005-11-24 Kurume University Target gene mimitin of myc
WO2007086342A1 (en) * 2006-01-27 2007-08-02 National University Corporation Chiba University METHOD OF DETECTING CANCER USING SPLICING VARIANT OF c-myc GENE TRANSCRIPTIONAL REGULATOR FIR OR FOUR-BASE REPETITIVE SEQUENCE IN INTRON 2
CA2742489A1 (en) * 2008-11-14 2010-05-20 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
JP2014156400A (en) * 2011-05-24 2014-08-28 Astellas Pharma Inc Labeled derivative for image diagnosis of tumor
FI20115876A0 (en) * 2011-09-06 2011-09-06 Turun Yliopisto Combination therapy
JP2016104703A (en) * 2013-03-13 2016-06-09 アステラス製薬株式会社 Antitumor agent
US20160024591A1 (en) * 2013-03-14 2016-01-28 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
WO2017048800A1 (en) * 2015-09-15 2017-03-23 Swedish Health Services Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof

Also Published As

Publication number Publication date
CN113226318A (en) 2021-08-06
JP2024023480A (en) 2024-02-21
EP3836909A4 (en) 2022-07-27
BR112021002622A2 (en) 2021-05-11
CA3109605A1 (en) 2020-02-20
WO2020036852A1 (en) 2020-02-20
KR20210044251A (en) 2021-04-22
EP3836909A1 (en) 2021-06-23
AU2019321289A1 (en) 2021-04-08
US20210180141A1 (en) 2021-06-17
JP2021533774A (en) 2021-12-09
MX2021001749A (en) 2021-05-27

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination cancer therapy
SG11202101397TA (en) Biomarkers for cancer therapy
GB201808476D0 (en) Biomarkers for colorectal cancer
ZA202005847B (en) Cancer therapy
GB201919219D0 (en) Cancer biomarkers
IL277861A (en) Axl-specific antibodies for cancer treatment
IL282093A (en) Combination therapy for cancer
PT3609497T (en) Combination therapy for prostate cancer
GB201820660D0 (en) Cancer treatments
GB201905780D0 (en) Cancer therapy
EP3713576A4 (en) Methods for cancer therapy
SG11202010528XA (en) Combinations for treating cancer
GB201800733D0 (en) Cancer
GB2580963B (en) Cancer therapies
GB201814487D0 (en) Cancer
IL259661A (en) Biomarkers for treating cancer with apilimod
GB201704909D0 (en) Cancer therapy
GB201703907D0 (en) Novel therapies for cancer
GB2595425B (en) Prostate cancer biomarkers
EP3847282A4 (en) Biomarkers for cancer therapy
GB201913957D0 (en) Cancer
EP3775282C0 (en) Biomarkers for diabetes therapy
GB201711855D0 (en) Cancer therapy
AU2018903318A0 (en) Biomarkers for cancer therapy
GB201817968D0 (en) Cancer biomarkers